Accutane/Generics Risk Program Should Include Mandatory Follow-Up Survey
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee suggests enhancements to Roche's SMART program to better prevent pregnancies. The proposal calls for a shared brand/generic system for patient registration.
You may also be interested in...
Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005
The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.
Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005
The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.
Ventiv Dermatology Sales Force To Promote Ranbaxy’s Isotretinoin
The firms sign multi-year agreement to market Sotret. Ventiv says it has established a specialty dermatology sales force to promote the product.